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Differentiation syndrome (DS) can be a
life-threatening complication in patients
with acute promyelocytic leukemia (APL)
undergoing induction therapy with all-
trans retinoic acid (ATRA). Detailed knowl-
edge about DS has remained limited. We
present an analysis of the incidence, char-
acteristics, prognostic factors, and out-
come of 739 APL patients treated with
ATRA plus idarubicin in 2 consecutive
trials (Programa Español de Tratamientos
en Hematología [PETHEMA] LPA96 and
LPA99). Overall, 183 patients (24.8%) ex-
perienced DS, 93 with a severe form
(12.6%) and 90 with a moderate form
(12.2%). Severe but not moderate DS was
associated with an increase in mortality.
A bimodal incidence of DS was observed,
with peaks occurring in the first and third
weeks after the start of ATRA therapy. A
multivariate analysis indicated that a WBC
count greater than 5  109/L and an abnor-
mal serum creatinine level correlated with
an increased risk of developing severe
DS. Patients receiving systematic pred-
nisone prophylaxis (LPA99 trial) in con-
trast to those receiving selective prophy-
laxis with dexamethasone (LPA96 trial)
had a lower incidence of severe DS. Pa-
tients developing severe DS showed a
reduced 7-year relapse-free survival in
the LPA96 trial (60% vs 85%, P  .003),
but this difference was not apparent in
the LPA99 trial (86% vs 88%). (Blood.
2009;113:775-783)
Introduction
Differentiation syndrome (DS), formerly known as retinoic acid
syndrome, can be a life-threatening complication in patients with
acute promyelocytic leukemia (APL) undergoing induction therapy
with all-trans retinoic acid (ATRA) or arsenic trioxide. The
full-blown syndrome is characterized by unexplained fever, weight
gain, peripheral edema, dyspnea with interstitial pulmonary infil-
trates, pleuropericardial effusion, hypotension, and acute renal
failure.1 The reported incidence of this syndrome of uncertain
pathogenesis ranges from 2% to 27%.1-10 This wide range is
probably because of the different criteria used for the diagnosis of
DS, and to the effects on the incidence and severity of the syndrome
due to differences in induction therapy and supportive measures. In
this regard, the early addition of chemotherapy to ATRA and the
administration of high-dose dexamethasone at the onset of the first
symptoms appear to have reduced the DS-related mortality to 1%
or less in the most recent trials.9-11
Although the mortality associated with DS is now relatively
low, the development of this complication has additional implica-
tions, such as an increase in morbidity leading to an increased use
of hospital resources, and it has been suggested that this is
associated with an increased risk of relapse independent of the
white blood cell (WBC) count.11 However, this interesting finding
reported by the European APL Group has not yet been confirmed in
other studies.
Apart from a peak WBC count frequently observed at the onset
of DS symptoms,2 very little is known about other factors
predictive of DS when patients are treated with ATRA combined
with chemotherapy. In this context, only one published study
included a significant number of patients and examined possible
prognostic factors, including pretreatment WBC count, associated
with the development of DS.10 This study found that none of the
examined variables had prognostic value. Furthermore, the Pro-
grama Español de Tratamientos en Hematología (PETHEMA)
group has recently analyzed the causes and prognostic factors of
induction failure, including death due to DS, but the incidence,
time of occurrence, and prognostic factors of the development of
this syndrome were not analyzed.12
This study was designed to analyze the incidence, clinical
manifestations, and prognostic factors associated with DS, as well
as the short- and long-term outcomes for patients developing this
syndrome in a large series of patients with newly diagnosed APL
treated with ATRA and idarubicin (AIDA regimen) who were
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enrolled in 2 consecutive studies by the PETHEMA Group (LPA96
and LPA99). We also analyzed the impact of the different regimens
of corticosteroid prophylaxis used in these trials on the develop-
ment and severity of DS.
Methods
Eligibility
For enrolment in the consecutive PETHEMA LPA96 and LPA99 trials,
patients were required to have a diagnosis of de novo APL with demonstra-
tion of the t(15;17) or promyelocytic leukemia–retinoic acid receptor-
(PML-RARA) rearrangements, normal hepatic and renal function, no
cardiac contraindications to anthracycline chemotherapy, and an Eastern
Cooperative Oncology Group (ECOG) performance status of less than 4.
Informed consent was obtained from all patients in accordance with the
Declaration of Helsinki. The protocol was approved by the Research Ethics
Board of each participating hospital.
Induction therapy
Treatment with ATRA was started as soon as a diagnosis of APL by
morphologic criteria was made.13,14 Induction therapy consisted of oral
ATRA (45 mg/m2 per day) divided into 2 daily doses, which was
maintained until complete hematologic remission or for a maximum of
90 days, and idarubicin (12 mg/m2 per day) given as an intravenous
bolus on days 2, 4, 6, and 8 (AIDA regimen). For patients 20 years of age
or younger, the ATRA was adjusted to 25 mg/m2 per day. Since
November 1999 (LPA99 trial), the dose of idarubicin on day 8 has been
omitted for patients more than 70 years of age.
Postremission therapy
Details of the consolidation and maintenance therapy have been described
elsewhere.15 Briefly, the first consolidation course consisted of idarubicin
(5 mg/m2 per day for 4 days), the second of mitoxantrone (10 mg/m2 per day
for 5 days), and the third of idarubicin (12 mg/m2 per day for 1 day). From
November 1999 (LPA99 study), intermediate- and high-risk patients, as
previously defined,16 received ATRA (45 mg/m2 per day for 15 days)
combined with the reinforced single-agent chemotherapy courses. Patients
who tested negative for PML-RARA at the end of consolidation were started
on maintenance therapy with oral mercaptopurine (50 mg/m2 per day),
intramuscular methotrexate (15 mg/m2 per week), and oral ATRA
(45 mg/m2 per day for 15 days every 3 months) over 2 years.
Management of DS and other supportive measures
Treatment with intravenous dexamethasone at a dose of 10 mg twice daily
was started promptly at the very earliest symptom or sign of DS. ATRA was
discontinued in cases where there was progression of the clinical symptoms
of DS. In the LPA96 trial, patients with a WBC count greater than
5  109/L (before or during treatment with ATRA) received prophylaxis
with dexamethasone (10 mg/12 hours intravenously for 7 days), while in
the LPA99 study all patients, regardless of WBC count, received DS
prophylaxis with prednisone (0.5 mg/kg per day orally) from days 1 through
15. Diuretics were usually administered to treat acute renal failure and
weight gain, and dialysis or venous continuous ultrafiltration was per-
formed at the physicians’ discretion. Mechanical ventilation was indicated
in some patients with severe acute respiratory failure. Details about the
management of coagulopathy, transfusion policy, and other supportive
measures have been described elsewhere.12
Study definitions and endpoints
The remission induction response was assessed according to the criteria recently
revised by Cheson et al17 A morphologic complete remission (CR) designation
requires a patient to have less than 5% blasts and atypical promyelocytes in an
aspirate sample, an absolute neutrophil count of more than 109/L and a platelet
count of more than 100 109/L. The treatment failure group included those
patients for whom treatment had failed to achieve a CR. The primary end point of
the study was the incidence of DS. Diagnosis of this syndrome was made
according to the presence of the following signs and symptoms described by
Frankel et al1: dyspnea, unexplained fever, weight gain greater than 5 kg,
unexplained hypotension, acute renal failure, and, particularly, a chest radiograph
demonstrating pulmonary infiltrates or pleuropericardial effusion. Patients with
4 or more of the above signs or symptoms were classified as having severe DS,
while those with 2 or 3 signs or symptoms were considered to have moderate DS.
No single sign or symptom was considered sufficient to make a diagnosis of the
syndrome. Patients with alternative explanations for the clinical complex, such as
pulmonary hemorrhage, septic shock, pneumonia, or cardiac failure, were
considered to not have DS. Death was attributed to DS when death occurred in
patients with severe DS and was not explained by infection, hemorrhage, or other
causes. DS was defined as “early” when it occurred within 7 days of the start of
ATRA, or “late” when it occurred more than 7 days after the start of ATRA.
Data collection and prognostic factors
Data were collected and registered prospectively. Thirty-six patient and disease
characteristics documented at the initial evaluation were examined for prognostic
factor analysis to establish their relationship to the development of DS. Basic
demographic data and clinical characteristics at presentation included age, sex,
ECOG score, fever, total body surface, and liver and spleen enlargement. Serum
biochemical parameters were creatinine, uric acid, lactate dehydrogenase (LDH),
alkaline phosphatase, total bilirubin, and albumin. Peripheral blood (PB) features
included hemoglobin level, platelet count, WBC count, and blast cell percentage.
Bone marrow aspirate parameters evaluated were cellularity, peroxidase reactiv-
ity, blast cell percentage, French-American-British (FAB) subtype, cytogenetics,
FLT3-internal tandem duplication (FLT3-ITD) mutations, and PML-RARA
isoforms. The following surface antigen markers were evaluated by multiparamet-
ric flow inmunocytometry: CD2, CD7, CD11b, CD13, CD14, CD15, CD19,
CD34, CD56, and CD117. Positivity for a specific antigen was defined as
expression of the corresponding surface marker by more than 20% of blast cells.
Other variables such as PETHEMA LPA trial (LPA96 vs LPA99), fibrinogen
level, and the presence of coagulopathy were also included. Coagulopathy was
defined as a prolonged prothrombin time and/or activated partial thromboplastin
time in addition to hypofibrinogenemia and/or increased levels of fibrin
degradation products or D-dimer. The prognostic impact of DS on induction
mortality and risk of relapse was also analyzed.
Statistical methods
Chi-square with Yates’ correction, when appropriate, was used to analyze
differences in the distribution of variables among patient subsets. The
Student t test and Mann-Whitney U test were used to compare continuous
variables with normal and nonnormal distribution, respectively. P values
were calculated using the 2-tailed test. Characteristics selected for inclusion
in the multivariate analysis were those for which there was some indication
of a significant association with DS in univariate analysis (P  .1) and, if
available, those for which prior studies had suggested a possible relation-
ship. Multivariate analysis was performed using a logistic regression
model.18 Missing data were substituted by the mean values from patients for
whom data were available.19 For univariate comparison, unadjusted time-to-
event analyses (relapse-free survival [RFS]) were performed using the
Kaplan-Meier estimate,20 as well as log-rank tests and their generaliza-
tions.21 Patient follow-up was updated in February 2008 and the median
follow-up of the cohort was 80 months (range, 29-133 months). Computa-
tions were performed using 4F, 3D, LR, 1L, and 2L programs from the
BMDP statistical library (BMDP Statistical Software, Los Angeles, CA).22
Results
Accrual and patient characteristics
Between November 1996 and June 2005, 793 consecutive patients
with a genetic diagnosis of APL were registered from 82 institu-
tions in Spain, The Netherlands, Belgium, Argentina, Uruguay, and
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the Czech Republic (the names of the institutions and clinicians
involved are listed in the Appendix, available on the Blood website;
see the Supplemental Materials link at the top of the online article).
Forty-two patients (5%, 8 [4%] in the LPA96 and 34 [6%] in the
LPA99 trials) were considered ineligible for the treatment because
their severe clinical condition contraindicated the administration of
chemotherapy. Thus, 751 patients who met the previously defined
entry criteria were enrolled in the LPA96 and LPA99 studies.
Twelve patients (5 of 180 in the LPA96 trial and 7 of 571 in the
LPA99 trial) were not evaluated because of protocol violations
during induction therapy. Details of ineligible and nonevaluable
patients are described elsewhere.12 LPA96 and LPA99 patients
were comparable for all the baseline characteristics except for sex
and serum albumin levels (female sex and low albumin levels were
more frequent in the LPA99 trial; both P  .01).
Incidence and characteristics of patients with DS
Overall, 183 of 739 patients (24.8%) experienced DS; 93 (12.6%)
were severe cases and 90 (12.2%) were moderate cases. In 33 patients
(4.5%) with possible DS, an unambiguous diagnosis of DS could
not be made. This was due to the presence of concurrent medical
problems that could explain the clinical manifestations. These
problems were pulmonary hemorrhage in 13 patients, pneumonia
in 8, congestive heart failure in 6, renal failure in 3, and septic
shock in 3.
Table 1. Initial characteristics of patients with and without differentiation syndrome (DS)
Characteristic
DS No DS
P
Total
Median
(range) No. (%)
Median
(range) No. (%)
Median
(range) No. (%)
Overall 183 (100) 556 (100) 739 (100)
Protocol
LPA96 53 (29) 122 (22) .05 175 (24)
LPA99 130 (71) 434 (78) 564 (76)
Age, y 43 (3-78) 39 (2-83) .04 40 (2-83)
Younger than 19 17 (9) 67 (12) 84 (11)
19-50 103 (56) 326 (58) 429 (58)
51-60 24 (13) 71 (13) 95 (13)
61-70 24 (13) 63 (11) 87 (12)
Older than 70 15 (8) 29 (5) 44 (6)
Sex
Male 100 (55) 274 (49) .21 374 (51)
Female 83 (45) 282 (51) 365 (49)
ECOG performance status 1 (0-3) 1 (0-3) .32 1 (0-3)
0-1 123 (72) 389 (76) 512 (75)
2 37 (22) 86 (17) 123 (18)
3 10 (6) 36 (7) 46 (7)
Fever
No 109 (60) 338 (61) .71 447 (61)
Yes 73 (40) 212 (38) 285 (39)
WBC count,109/L 3.3 (0.4-133) 2.0 (0.2-460) .001 2.2 (0.2-460)
Less than 2 69 (38) 281 (51) 350 (47)
2-5 35 (19) 105 (19) 140 (19)
5-10 16 (9) 46 (8) 62 (8)
10-50 48 (26) 85 (15) 133 (18)
More than 50 15 (8) 38 (7) 53 (7)
Platelet count,109/L 20 (1-207) 23 (1-207) .19 22 (1-207)
Less than 10 32 (17) 102 (18) 134 (18)
10-40 116 (59) 318 (67) 434 (59)
More than 40 35 (19) 135 (24) 170 (23)
Hemoglobin, g/dL 9.5 (4-16.9) 9.0 (3-15.9) .12 9.3 (3-16.9)
Less than or equal to 10 112 (61) 357 (64) 469 (64)
More than 10 71 (39) 198 (36) 269 (36)
Creatinine, mg/dL 1.0 (0.2-2) 0.9 (0.2-2.4) .03 0.9 (0.2-2.4)
Less than or equal to 1.4 170 (96) 532 (99) 702 (98)
More than 1.4 7 (4) 7 (1) 14 (2)
Albumin, mg/dL 4.0 (2.3-6.7) 4.0 (1.7-6.2) .99 4.0 (1.7-6.7)
Less than or equal to 3.5 34 (23) 93 (21) 127 (21)
More than 3.5 134 (77) 356 (79) 470 (79)
Coagulopathy
No 31 (17) 140 (25) .02 171 (23)
Yes 151 (83) 412 (75) 563 (77)
FAB subtype
Hypergranular 143 (78) 455 (83) .11 598 (82)
Microgranular 40 (22) 91 (17) 131 (18)
PML-RARA isoform
BCR1/BCR2 90 (55) 292 (59) .35 382 (58)
BCR3 73 (45) 200 (41) 271 (42)
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Table 1 shows that age, serum creatinine levels, and WBC counts
were higher among patients who developed DS than among those who
did not (P .04, P .03, and P .001, respectively). Patients with DS
presented more frequently with coagulopathy (P .02).
Clinical manifestations and timing of DS
The most frequent clinical manifestations of severe DS were
dyspnea (95%), pulmonary infiltrates (81%), unexplained fever
(74%), weight gain of more than 5 kg (68%), pleural effusion
(58%), and renal failure (46%). The frequencies of these
symptoms were considerably lower in moderate than in severe
DS (Table 2). As shown in Table 2, the frequency of hypotension
in late severe DS was significantly higher than in early severe
DS (P  .007), whereas the frequencies of other signs and
symptoms did not differ significantly between patients with late
and early severe DS.
DS occurred at a median of 12 days after starting ATRA treatment
(range, 0-46 days). Severe DS occurred comparatively early, at a median
of 6 days, while moderate DS appeared after a median of 15 days.
A bimodal time distribution of the peak incidence of DS was observed
(Figure 1) in both moderate and severe DS. The first peak occurred
during the first week of ATRA treatment in 47% of patients, and the
second peak of new cases of DS was seen in the third week (25% of
patients). During the second week, only 5% of new cases of DS were
noted. DS continued to develop in some patients in the fourth week
(19%) and after day 29 (3%).
Outcomes of DS
A total of 667 of the 739 evaluable patients achieved morpho-
logic CR (90.3%; 95% confidence interval [CI], 88.0%-92.4%).
Of the 72 induction failures, 66 patients died during induction
and the remaining 6 patients were registered by their physicians
as having resistant leukemia. These 6 patients were prematurely
assessed as having disease refractory to induction treatment (on
days 18-33 after chemotherapy), according to the classical
morphologic criteria for AML. In the 6 patients, DS had been
noted late (onset on days 12, 13, 15, and 15) and early (in
2 patients on day 5).
The development of moderate DS had no impact on the death rate
during induction (6% with moderate DS vs 7% with no DS, P .82),
but severe DS was associated with a higher death rate during induction
(26% with severe DS vs 7% with no DS, P .001). The induction
mortality was 40% in patients with early severe DS (Table 3). The
DS-associated mortality was 11% in patients with severe DS, while no
deaths resulted from moderate DS. Ten deaths related to DS occurring
during induction have been described in detail elsewhere.12 Hemorrhage-
associated mortality was also higher in patients who developed severe
DS than in those with moderate DS or no DS (11% vs 6% vs 4%,
respectively, P .02).
Intravenous dexamethasone was administered in 90% of pa-
tients with severe DS and 82% of patients with moderate DS (Table
3). ATRA was temporarily discontinued in 64% of patients with
severe DS and 60% of patients with moderate DS. Diuretics,
dialysis, and mechanical ventilation were more frequently used in
patients with severe DS than in those with moderate DS. Patients
with severe DS required more plasma, platelet, and red blood cell
transfusions during induction.
Table 3 shows that severe DS was significantly associated with
higher frequencies of thrombosis and grade 3 or 4 hepatotoxicity
during induction, as compared with no DS or moderate DS cases
(P  .008 for thrombosis and P  .01 for grade 3 or 4 hepatotoxic-
ity). Time to neutrophil recovery was significantly shorter in
patients with severe DS (P  .003). Patients with severe DS,
especially those with late DS, spent more days in the hospital
during induction treatment (P  .06).
Prognostic factors for DS
Factors predicting moderate DS. The univariate analysis of
prognostic factors identified the following characteristics as signifi-
cantly associated with moderate DS: high WBC count at presenta-
tion, with 10 109/L as the most significant cutoff point; LDH
Table 2. Clinical signs and symptoms of moderate and severe DS
Clinical signs and
symptoms
Frequency of the different clinical signs and symptoms according to the type of DS
Moderate DS
(n  90), no. (%)
Severe DS
(n  93), no. (%) P*
Early severe DS
(n  43), no. (%)
Late severe DS
(n  43), no. (%) P†
Dyspnea 53 (59) 88 (95) .001 48 (96) 40 (93) .53
Pulmonary infiltrates per X-ray 34 (38) 75 (81) .001 43 (86) 32 (74) .16
Edema 48 (53) 75 (81) .001 42 (84) 33 (77) .38
Unexplained fever 48 (53) 69 (74) .003 34 (68) 35 (81) .14
Weight gain of more than 5 kg 34 (38) 63 (68) .001 37 (80) 26 (67) .15
Pleural effusion 24 (27) 54 (58) .001 32 (64) 22 (51) .21
Renal failure 8 (9) 43 (46) .001 19 (40) 24 (57) .12
Hypotension 11 (12) 36 (39) .001 13 (26) 23 (53) .007
Pericardial effusion 10 (11) 21 (23) .04 8 (16) 13 (30) .10
*P value comparing severe DS versus moderate DS.
†P value comparing early severe DS versus late severe DS.
Figure 1. Time to occurrence of moderate and severe differentiation syndrome.
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greater than the upper laboratory normal (ULN) values; and PB
blasts greater than 70% (Table 4).
Multivariate analysis identified a WBC count greater than
10  109/L as an independent prognostic factor for moderate DS
(P  .039; Table 5).
Factors predicting severe DS. Univariate analysis identified
the following prognostic factors as regards severe DS: high WBC
count at presentation, with 5 109/L as the most significant cutoff
point; abnormal levels of serum creatinine; FLT3-ITD mutations;
microgranular FAB subtype; short PML-RARA isoform; and male
sex (Table 4).
Upon multivariate analysis, abnormal levels of serum creatinine
(P  .004), WBC count greater than 5 109/L (P  .021), and
treatment with the LPA96 protocol (P  .044) remained indepen-
dent prognostic factors for severe DS (Table 5).
Risk of relapse of APL in patients developing DS
The overall 7-year RFS in patients with and without DS was 85%
and 87%, respectively (P  .31; Figure 2A). Patients developing
severe DS showed a significantly lower 7-year RFS in the LPA96
trial (60% vs 85%, P  .003; Figure 2B). This difference was not
apparent for patients treated on the LPA99 trial (86% vs 88%;
P  .54; Figure 2C). None of the 10 patients who had central
nervous system relapse had previously experienced DS.
Discussion
This study shows that roughly one quarter of patients with APL
undergoing induction therapy with the AIDA regimen develop DS, with
an equal distribution of the moderate and severe forms of DS. Patients
with moderate DS showed the same treatment outcome in terms of
mortality during induction and relapse probability. Severe DS was
associated with increased mortality during induction. A bimodal time
distribution of incidence of both moderate and severe DS was observed,
with peaks in the first and third week of ATRA treatment. A lower
overall incidence of severe DS was observed in patients enrolled in the
LPA99 trial, who systematically received prophylaxis with prednisone
from the initiation of ATRA treatment for 15 days, as compared with
those treated in the LPA96 trial, who received selective prophylaxis with
intravenous dexamethasone when the WBC count was more than
5 109/L (before or during treatment with ATRA). A WBC count
greater than 5 109/L and serum levels of creatinine greater than
1.4 mg/dL at diagnosis were identified as 2 independent factors pre-
dicting the development of severe DS. The development of severe DS
correlated with a higher risk of relapse, but evidence of this relationship
was restricted entirely to patients treated in the LPA96 trial, as it was not
apparent in patients treated with the LPA99 protocol. It should be noted
that patients with intermediate and high risks of relapse in the latter
protocol received ATRA and a reinforced dose of idarubicin for
consolidation, which may have contributed to the reduced relapse rate.
The variation in the incidence of DS associated with induction
therapy in APL that has been previously reported is quite wide with
a range from 2% to 27%.1-10 The impact of DS on the treatment
outcomes as reported has also varied. Differences in the effects of
DS between studies could be a result of several factors. The most
likely explanation for different results relates to the lack of
consensus in the definition, grading, and classification of the
syndrome. Furthermore, the concurrent use of chemotherapy with
ATRA in some but not other studies has probably determined
differences in the incidence and severity of DS. In this respect, the
results of a randomized study that focused on patients with low
WBC counts ( 5  109/L)11 and several nonrandomized stud-
ies9,23,24 strongly suggest that the concurrent use of ATRA and
chemotherapy decreases the incidence of DS. The GIMEMA
group,9 using the AIDA regimen, reported the low incidence of DS
of 2.5% (6 of 240 patients) but their definition of DS was notably
different. They established a diagnosis of severe DS according to
Table 3. Management, complications, and outcomes of moderate and severe DS
No DS
(n  556)
Moderate
DS (n  90)
Overall
(n  93) P*
Early severe
DS (n  50)
Late severe
DS (n  43) P†
Management of DS
ATRA withdrawal, no. (%) 87 (16) 54 (60) 60 (64)  .001 39 (78) 21 (49) .003
ATRA duration shorter than 30 days, no. (%)‡ 100 (26) 36 (49) 36 (60)  .001 11 (48) 15 (68) .87
Intravenous dexamethasone, no. (%) 90 (16) 74 (82) 84 (90)  .001 46 (92) 38 (88) .55
Diuretics, no. (%) NA 60 (67) 81 (87) .001 43 (86) 38 (88) .73
Dialysis, no. (%) NA 1 (1) 11 (12) .003 8 (16) 3 (7) .18
Mechanical ventilation, no. (%) NA 7 (8) 24 (26) .002 18 (36) 6 (14) .02
Outcome and complications of DS
Death during induction, no. (%) 37 (7) 5 (6) 24 (26)  .001 20 (40) 4 (9) .001
Death due to DS, no. (%) 0 (0) 0 (0) 10 (11)  .001 8 (16) 2 (5) .08
Death due to hemorrhage, no. (%) 22 (4) 5 (6) 10 (11) .02 9 (18) 1 (2) .04
Death due to infection, no. (%) 14 (2) 0 (0) 3 (3) .27 2 (4) 1 (2) .99
Thrombosis during induction, no. (%) 18 (3) 3 (3) 9 (10) .008 5 (10) 4 (9) .91
Grade 3-4 hepatotoxicity,§ no. (%) 24 (5) 5 (6) 11 (14) .01 5 (12) 6 (15) .65
Hospital days during induction, mean‡ 35.7 34.4 38.2 .06 35.6 40.4 .06
Days to PMNs greater than 1  109/L, mean‡ 23.5 21.6 20.0 .003 20.5 19.7 .61
Days to platelets greater than 50  109/L, mean‡ 18.7 17.8 19.9 .11 19.3 20.5 .35
Transfused platelet units during induction, mean‡ 40.7 44.5 58.9 .007 60.2 57.8 .98
Transfused plasma units during induction, mean‡ 4.4 10.1 12.7  .001 19.1 6.5 .01
Transfused RBC units during induction, mean‡ 9.2 10.3 12.3  .001 13.1 11.7 .92
PMNs indicates neutrophils; RBC, red blood cell; and NA, not available.
*P value comparing severe DS versus moderate DS versus no DS.
†P value comparing early severe DS versus late severe DS.
‡Excluding patients who did not achieve complete remission.
§World Health Organization gradation scale.
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Table 4. Incidence of moderate and severe DS according to baseline characteristics of patients (univariate analysis)
Characteristic
No. of
patients
Moderate DS Severe DS
No. (%) P No. (%) P
Overall 739 90 (12.2) 93 (12.6)
Protocol
LPA 96 175 24 (13.7) .48 29 (16.6) .07
LPA 99 564 66 (11.7) 64 (11.3)
Age, y
Younger than 19 84 9 (10.7) .18* 8 (9.5) .29†
19-50 429 54 (12.6) 49 (11.4)
51-60 95 6 (6.3) 18 (18.9)
61-70 87 12 (13.8) 12 (13.8)
Older than 70 44 9 (20.5) 6 (13.6)
Sex
Male 374 44 (11.8) .74 56 (15.0) .05
Female 365 46 (12.6) 37 (10.1)
ECOG performance status
0-1 512 62 (12.1) .74 61 (11.9) .31
2 123 16 (13.0) 21 (17.1)
3 46 4 (8.7) 6 (13.0)
Fever
No 447 56 (12.4) .81 53 (11.8) .47
Yes 285 34 (11.9) 39 (13.7)
WBC count, 109/L
Less than 2 350 37 (10.6) .15‡ 32 (9.1) .08§
2-5 140 16 (11.4) 19 (13.6)
5-10 62 6 (9.7) 10 (16.1)
10-50 133 25 (18.8) 23 (17.4)
More than 50 53 6 (11.3) 9 (17.0)
Platelets, 109/L
Less than 10 134 14 (10.4) .64 18 (13.4) .36
10-40 434 57 (13.1) 59 (13.6)
More than 40 170 19 (11.2) 16 (9.4)
Coagulopathy
No 171 14 (8.2) .08 17 (9.9) .24
Yes 563 76 (13.5) 75 (13.3)
Creatinine, mg/dL
Less than or equal to 1.4 702 86 (12.3) .87 84 (12.0) .002
More than 1.4 14 1 (7.1) 6 (42.9)
Albumin, mg/dL
Less than or equal to 3.5 127 14 (11.0) .68 20 (15.7) .32
More than 3.5 470 58 (12.3) 56 (11.9)
LDH  ULN
Less than or equal to 1 347 29 (8.4) .004 38 (11.0) .21
More than 1 347 59 (15.9) 49 (14.1)
FAB subtype
Hypergranular 598 74 (12.4) .99 69 (11.5) .05
Microgranular 131 16 (12.3) 24 (18.3)
PML-RAR isoform
BCR1/BCR2 382 51 (13.4) .45 39 (10.2) .05
BCR3 273 31 (11.4) 42 (15.4)
Blasts, % of PB
Less than or equal to 70 494 52 (10.5) .02 61 (12.3) .33
More than 70 184 31 (16.8) 28 (15.2)
FLT3-ITD
Negative 224 29 (12.9) .86 26 (12.6) .05
Positive 66 8 (12.1) 14 (24.6)
CD2
Negative 107 44 (13.1) .29 43 (12.8) .61
Positive 337 19 (17.8) 11 (10.3)
ULN indicates upper laboratory normal (values).
*Age  70 years versus age  70 years (20.0% versus 11.7%, P  .09).
†Age  50 years versus age  50 years (15.9% versus 11.1%, P  .07).
‡WBC  10  109/L versus WBC  10  109/L (16.7% versus 10.7%, P  .03).
§WBC  5  109/L versus WBC  5  109/L (16.9% versus 10.4%, P  .01).
Platelets  40  109/L versus platelets  40  109/L (13.6% versus 9.4%, P  .15).
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the presence of 5 of the 7 signs and symptoms as originally
described by Frankel et al.1 As a matter of fact, when we apply the
same definition to our series of 739 patients, we calculate a similar
incidence of 2.6%. In other published studies of concurrent
ATRA/chemotherapy regimens, greater incidences of DS have
been reported (11% to 16%), but the diagnostic criteria for the
syndrome often were not specifically defined23,24 or the diagnostic
criteria were less strict (3 of 7 signs and symptoms).10 In the present
study, we first assessed the most discriminating cutoff value for
predicting outcomes. We then classified the DS as moderate or
severe according to the presence of 2 to 3, or more than 3 of the
7 signs and symptoms, respectively. This distinction allowed for
the assessment of the different prognostic significance of severe
DS. The development of severe but not moderate DS appeared to
be associated with an increased mortality. Interestingly, apart from
a proportion of patients who died in the context of severe DS with
apparently no other contributing cause of death, this complication
was also associated with death resulting from hemorrhage. In line
with this finding, a Japanese group25 reported that patients with DS
were more prone to develop severe hemorrhage during induction.
In the present study, we found that severe DS, especially early DS,
was associated with coagulopathy and a higher use of plasma,
platelet, and red blood cell transfusions during induction. The
exacerbation of the procoagulant state of APL that can be observed
with the development of DS26-29 may lead not only to an increased
risk of hemorrhage but also to a higher incidence of thrombosis.
This association of DS and activated procoagulation is also evident
in the present study. On the other hand, as far as we know, a shorter
period of neutropenia has not previously been reported, while the
association of severe DS with an increased rate of grades 3 and 4
hepatotoxicity was also noted in the early study by Frankel et al.1
The bimodal peak of incidence that we observed in the first and
third week of ATRA treatment in both moderate and severe DS is
remarkable. It should be noted that cases of early severe DS more
frequently required mechanical ventilation and were associated
with higher mortality during induction than those occurring during
the third week or beyond. In addition, early severe DS was
characterized by a higher frequency of pulmonary infiltrates and
weight gain, probably related to an initial rise in leukocytosis and
fluid overload. In contrast, hypotension, unexplained fever, pericar-
dial effusion, and renal failure were more frequent in late severe
DS. We should emphasize that in this situation distinguishing
between DS and other clinical complications, particularly sepsis,
may be difficult. Therefore, in these cases, treatment of DS should
be complemented with therapeutic measures addressing alternative
diagnoses that could also explain the symptoms.
The study of prognostic factors for DS in patients treated
with ATRA plus chemotherapy has scarcely been addressed in
the literature. A study by the European APL Group10 analyzed
prognostic factors of DS in a significant number of patients who
were randomized to receive either ATRA followed by chemo-
therapy or both simultaneously. That study did not reveal any
significant prognostic factor for DS (defined as the presence of
at least 3 of 7 clinical manifestations) in any of the treatment
arms. In the current study, we report several pretreatment
variables predictive of the severe form of the syndrome,
Table 5. Multivariate analysis of factors predicting the occurrence of DS
Covariate
Unfavorable
category
Overall DS Moderate DS Severe DS
OR (95% CI) P OR (95% CI) P OR (95% CI) P
WBC count  5  109/L 1.8 (1.1-2.7) .021
WBC count  10  109/L 1.85 (1.3-2.7) .012 1.7 (1.04-2.7) .039
Creatinine  1.4 mg/dL 5.8 (1.9-16.9) .004
Protocol LPA96 1.7 (1.04-2.7) .044
OR indicates odds ratio
Table 4. Incidence of moderate and severe DS according to baseline characteristics of patients (univariate analysis) (continued
Characteristic
No. of
patients
Moderate DS Severe DS
No. (%) P No. (%) P
CD11b
Negative 296 33 (11.1) .69 34 (11.5) .74
Positive 41 6 (14.6) 6 (14.6)
CD13
Negative 38 5 (13.2) .99 3 (7.9) .49
Positive 478 62 (13.0) 63 (13.2)
CD15
Negative 322 46 (14.3) .50 37 (11.5) .59
Positive 140 16 (11.4) 13 (9.3)
CD56
Negative 352 49 (13.9) .99 39 (11.1) .45
Positive 43 6 (14.0) 7 (16.3)
CD34
Negative 439 56 (12.8) .18 52 (11.8) .64
Positive 91 17 (18.7) 13 (14.3)
ULN indicates upper laboratory normal (values).
*Age  70 years versus age  70 years (20.0% versus 11.7%, P  .09).
†Age  50 years versus age  50 years (15.9% versus 11.1%, P  .07).
‡WBC  10  109/L versus WBC  10  109/L (16.7% versus 10.7%, P  .03).
§WBC  5  109/L versus WBC  5  109/L (16.9% versus 10.4%, P  .01).
Platelets  40  109/L versus platelets  40  109/L (13.6% versus 9.4%, P  .15).
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including WBC count ( 5  109/L), abnormal serum creati-
nine levels, the FLT3-ITD mutation, the microgranular FAB
subtype, the short PML-RARA isoform, and male sex. The
significant variables were reduced to WBC counts and serum
creatinine levels in multivariate analysis. None of these factors
have been previously reported as predictive of DS. With regard
to an abnormal levels of serum creatinine as an independent
predictive factor of severe DS, this finding should be cautiously
interpreted due to the small proportion of patients who had this
clinical complication (6 of 90 patients with this data available
who developed the severe form of the syndrome). Renal failure
due, in part, to the capillary leak syndrome caused by cytokine
release in DS may explain the association between high serum
creatinine and severe DS. On the other hand, results of the US
Intergroup study indicated that the microgranular subtype of
APL protected against the development of DS.8 Patients in that
study, however, had been treated with ATRA alone. With respect
to presenting WBC counts, the European APL trial showed that
patients with greater than 5  109/L and DS tended to need
mechanical ventilation more frequently than those with lower
WBC counts and DS, but this was not statistically significant
and the WBC count was not associated with the development of
DS.10 Apart from a mere statistical finding, we have no
explanation for the paradoxical lower cutoff point of presenting
WBC counts to predict severe DS (5  109/L) compared with
moderate DS (10  109/L). Clinical and experimental studies
have suggested an association between the development of DS
and the expression of adhesion molecules such as CD132 and
CD11b.30,31 We found no relationship between the expression of
any of the surface markers analyzed and the development of DS.
Although the preemptive use of corticosteroids at the earliest
clinical manifestations of DS has been adopted as the standard
management,32 their use as prophylaxis is more controversial.
The only available evidence supporting the use of corticosteroid
prophylaxis is based on a study by Wiley and Firkin7 that was
performed in 19 patients treated with ATRA alone. This study
showed a reduction in pulmonary toxicity by administration of
prednisone when the WBC count rose above 10  109/L.
Probably based on these results, several trials have included
prophylaxis with dexamethasone in patients with more than 5 to
10  109/L.23,33 We compared the outcome following a preemp-
tive prophylactic strategy as used in the PETHEMA LPA96 trial
with the systematic prophylactic approach of the LPA99 trial, in
which all patients received prednisone from the start of ATRA,
regardless of WBC count. The retrospective analysis demon-
strated a statistically significant reduction in the incidence of
severe DS, but not in DS-related mortality,12 in relation to the
systematic use of prednisone during an early 15 day interval.
The European APL Group has reported an increased relapse
rate in patients developing DS.10,11 We have confirmed this
finding in patients developing severe DS treated according the
LPA96 trial, but not in those enrolled in the LPA99 trial. In the
latter trial, however, patients with intermediate and high risks of
relapse received ATRA and a reinforced dose of idarubicin for
consolidation, which may have contributed to the reduced
relapse rate. Finally, we found no association between DS and
central nervous system relapse, as suggested by others.10,34
In conclusion, DS is a relatively frequent and serious
complication in patients with APL undergoing induction with
ATRA plus chemotherapy. Prophylaxis with prednisone has no
impact on reducing mortality resulting from DS, but it is likely
to reduce the incidence of severe DS. Although the question of
whether the use of corticosteroid prophylaxis is advantageous
should be definitively settled in randomized studies, this strat-
egy can be considered in patients treated with ATRA plus
chemotherapy, particularly taking into account that infectious
mortality was not apparently increased when prednisone prophy-
laxis was systematically used.12 Due to the association of severe
DS with an increase in morbidity and mortality during induc-
tion, risk-adapted strategies focused on patients with adverse
Figure 2. Kaplan-Meier estimates of relapse-free survival depending on develop-
ment of differentiation syndrome during induction. (A) In both PETHEMA LPA96 and
LPA99 trials; (B) in the PETHEMALPA96 trial; (C) in the PETHEMALPA99 trial.
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risk factors (WBC counts  5  109/L; abnormal levels of
serum creatinine) deserve further research.
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